DUBLIN--(BUSINESS WIRE)--The "Matrix Metalloproteinase (MMP) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
Matrix Metalloproteinase (MMP) Inhibitor - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Matrix Metalloproteinase (MMP) Inhibitor development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active Matrix Metalloproteinase (MMP) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.
Reasons to Buy
- Establish a comprehensive understanding of the current pipeline scenario across Matrix Metalloproteinase (MMP) Inhibitor to formulate effective R&D strategies
- Assess challenges and opportunities that influence Matrix Metalloproteinase (MMP) Inhibitor research & development (R&D)
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Identify and understand the sought after therapy areas and indications for Matrix Metalloproteinase (MMP) Inhibitor
- Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
- Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Matrix Metalloproteinase (MMP) Inhibitor to enhance and expand business potential and scope
- Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress
Topics Covered
1. Report Introduction
2. Matrix Metalloproteinase (MMP) Inhibitor - Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for Matrix Metalloproteinase (MMP) Inhibitor
4. Comparative Analysis
5. Matrix Metalloproteinase (MMP) Inhibitor Pipeline Products in Clinical Stages
5.1 Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
6. Matrix Metalloproteinase (MMP) Inhibitor Pipeline Products in Non-clinical Stages
6.1 Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment: Active Products
- Pipeline Assessment by Route of Administration
- Pipeline Assessment by Stage and Route of Administration
- Pipeline Assessment by Molecule Type
- Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline Products
8.1 Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
-
Reason for dormancy/discontinuation
Companies Featured
- Dyax
- Arriva Pharmaceuticals
- Quick-Med Technologies
- AngioLab Inc.
- Cervelo Pharmaceuticals
- Corbus Pharmaceuticals
- Ilkos Therapeutics
- Servier
- Aquilus Pharmaceuticals
- Pharmahungary Group
- Solvotrin Innovations
- Dyax
- Gilead Sciences
- D-Pharm
- Flexion Therapeutics
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/xlg2bd/matrix?w=4
